40 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
SNY Sanofi $43.75 $109.14B Downtrend
Article Searches
Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV http://www.zacks.com/stock/news/349786/pharma-stock-roundup-jnj-bmys-q4-earnings-study-failures-at-lly-abbv?cid=CS-ZC-FT-349786 Jan 25, 2019 - J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.
Can Sanofi (SNY) Keep the Earnings Surprise Streak Alive? http://www.zacks.com/stock/news/352151/can-sanofi-sny-keep-the-earnings-surprise-streak-alive?cid=CS-ZC-FT-352151 Feb 05, 2019 - Sanofi (SNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Sanofi's Myeloma Candidate Meets Goal in Phase III Study http://www.zacks.com/stock/news/352133/sanofis-myeloma-candidate-meets-goal-in-phase-iii-study?cid=CS-ZC-FT-352133 Feb 05, 2019 - Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea http://www.zacks.com/stock/news/352622/regeneron-q4-earnings-sales-beat-on-strong-dupixent-eylea?cid=CS-ZC-FT-352622 Feb 06, 2019 - Regeneron's (REGN) earnings and sales surpass expectations in Q4 on solid Dupixent and Eylea sales.
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs http://www.zacks.com/stock/news/353203/pharma-stock-roundup-q4-earnings-at-mrk-lly-chmp-nod-for-several-drugs?cid=CS-ZC-FT-353203 Feb 08, 2019 - Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Congress Grills Drugmakers: 5 Key Takeaways https://www.fool.com/investing/2019/02/26/congress-grills-drugmakers-5-key-takeaways.aspx?source=iedfolrf0000001 Feb 26, 2019 - Top drug companies addressed sky-high drug prices on Capitol Hill today.
Regeneron-Sanofi Get CHMP Nod for Dupixent Label Expansion http://www.zacks.com/stock/news/357622/regeneron-sanofi-get-chmp-nod-for-dupixent-label-expansion?cid=CS-ZC-FT-357622 Mar 04, 2019 - The CHMP gives a positive opinion for the label expansion of Regeneron (REGN) and Sanofi's Dupixent for the treatment of asthma in Europe.
3 Big Pharmas Trying to Pop the Rebate Bubble https://www.fool.com/investing/2019/03/06/3-big-pharmas-trying-to-pop-the-rebate-bubble.aspx?source=iedfolrf0000001 Mar 06, 2019 - Pharmaceutical companies are suddenly eager to lower drug prices.
Top Stock Reports for Salesforce, Booking Holdings & VMware http://www.zacks.com/research-daily/218411/top-stock-reports-for-salesforce-booking-holdings-vmware?cid=CS-ZC-FT-218411 Mar 06, 2019 - Top Stock Reports for Salesforce, Booking Holdings & VMware
Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA http://www.zacks.com/stock/news/357971/roches-rhhby-snda-for-flu-candidate-accepted-by-the-fda?cid=CS-ZC-FT-357971 Mar 06, 2019 - The FDA accepts Roche's (RHHBY) sNDA for Xofluza to treat influenza in people at high risk of complications.

Pages: 1234

Page 1>